Table 1. Erythromycin resistance among Streptococcus pneumoniae isolates, year 5 (2004–2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*.

US region†	Isolates, no. resistant/no. submitted (%)
	Year 5	Year 6
Northeast	518/1,931 (26.8)	662/2,102 (31.5)
North Central	467/1,314 (35.5)	568/1,395 (40.7)
Northwest	94/417 (22.5)	108/422 (25.6)
Southeast	340/998 (34.1)	419/1,064 (39.4)
South Central	402/1,149 (35.0)	529/1,368 (38.7)
Southwest	86/448 (19.2)	95/396 (24.0)
Total	1,907/6,257 (30.5)	2,381/6,747 (35.3)

   *PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States.
   †States submitting isolates for testing included Northeast: CT, DE, IN, MA, MD, MI, NJ, NY, OH, PA, RI, VT, and DC; North Central: IA, IL, KS, MN, MD, ND, NE, SD, and WI; Northwest: AK, ID, MT, OR, WA, and WY; Southeast: FL, GA, KY, NC, SC, VA, and WV; South Central: AL, AR, LA, OK, TN, and TX; Southwest: AZ, CA, CO, NM, NV, and UT.